-+ 0.00%
-+ 0.00%
-+ 0.00%

Puma Biotechnology Q1 net loss widens to $3.8 million; revenue falls to $44.8 million

PUBT·05/07/2026 20:26:57
Listen to the news
Puma Biotechnology Q1 net loss widens to $3.8 million; revenue falls to $44.8 million
  • Puma Biotechnology reported a net loss of USD 3.8 million, or USD 0.07 per share, swinging from net income of USD 3 million a year earlier.
  • Revenue slipped 2.61% to USD 44.8 million, including net product revenue of USD 42 million.
  • Operating costs and expenses climbed to USD 48.6 million from USD 42 million, led by research and development expense of USD 19.8 million due to higher alisertib study activity.
  • Cash, cash equivalents and marketable securities rose to USD 101.5 million at March 31 from USD 97.5 million at year-end, while total debt fell to USD 11.3 million from USD 22.5 million.
  • Guidance raised for full-year net product revenue to USD 202-206 million from USD 194-198 million, with net income seen at USD 16-19 million versus prior USD 10-13 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Puma Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605071605BIZWIRE_USPR_____20260507_BW681808) on May 07, 2026, and is solely responsible for the information contained therein.